- $20.56bn
- $3.18bn
- €3.82bn
- 92
- 80
- 21
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.95 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | 4.14 | ||
| Price to Sales | 5.06 | ||
| EV to EBITDA | 2.82 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.3% | ||
| Return on Equity | 4.62% | ||
| Operating Margin | 18.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 108.59 | 482.32 | 18,976.7 | 17,310.6 | 3,819 | 2,789.8 | 2,787.45 | 97.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +65351.47 | -3.84 | -89.53 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Directors
- Ugur Sahin CEO (55)
- Sierk Poetting CFO (47)
- Sean Marett CCO (55)
- Ryan Richardson MGB (41)
- Oezlem Tuereci MGB (53)
- Christoph Huber IND (76)
- Helmut Jeggle IND (51)
- Michael Motschmann IND (63)
- Ulrich Wandschneider IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 8th, 2019
- Public Since
- October 10th, 2019
- No. of Employees
- 6,133
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 237,725,735
- Address
- An der Goldgrube 12, MAINZ, 55131
- Web
- https://www.biontech.com/
- Phone
- +49 49613190840
- Contact
- Victoria Meissner
- Auditors
- Ernst & Young GmbH
Upcoming Events for BNTX
Q1 2024 BioNTech SE Earnings Release
BioNTech SE Annual Shareholders Meeting
BioNTech SE Annual Shareholders Meeting
Q2 2024 BioNTech SE Earnings Call
Q2 2024 BioNTech SE Earnings Release
Similar to BNTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the BioNTech SE share price?
As of Today at 19:03 UTC, shares in BioNTech SE are trading at $86.48. This share price information is delayed by 15 minutes.
How has the BioNTech SE share price performed this year?
Shares in BioNTech SE last closed at $86.48 and the price had moved by -33.3% over the past 365 days. In terms of relative price strength the BioNTech SE share price has underperformed the S&P500 Index by -46.13% over the past year.
What are the analyst and broker recommendations for BioNTech SE?
The overall consensus recommendation for BioNTech SE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the BioNTech SE dividend yield?
BioNTech SE does not currently pay a dividend.
Does BioNTech SE pay a dividend?
BioNTech SE does not currently pay a dividend.
When does BioNTech SE next pay dividends?
BioNTech SE does not currently pay a dividend.
How do I buy BioNTech SE shares?
To buy shares in BioNTech SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioNTech SE?
As of the previous close price of $86.48, shares in BioNTech SE had a market capitalisation of $20.56bn.
Where are BioNTech SE shares listed?
Here are the trading details for BioNTech SE:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BNTX
What kind of share is BioNTech SE?
Based on an overall assessment of its quality, value and momentum BioNTech SE is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioNTech SE share price forecast for 2024?
The analyst consensus target price for shares in BioNTech SE is $118.26. That is 36.75% above the last closing price of $86.48.
Analysts covering BioNTech SE currently have a consensus Earnings Per Share (EPS) forecast of -€1.49 for the next financial year.
What is the trend in the BioNTech SE share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioNTech SE. Over the past six months, its share price has underperformed the S&P500 Index by -28.73%.
As of the last closing price of $86.48, shares in BioNTech SE were trading -15.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioNTech SE PE Ratio?
The BioNTech SE PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $86.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioNTech SE?
BioNTech SE's management team is headed by:
- Ugur Sahin - CEO
- Sierk Poetting - CFO
- Sean Marett - CCO
- Ryan Richardson - MGB
- Oezlem Tuereci - MGB
- Christoph Huber - IND
- Helmut Jeggle - IND
- Michael Motschmann - IND
- Ulrich Wandschneider - IND